PRESS RELEASES

PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary ERYTECH Pharma Reports Voting Results from Annual General Meeting Held on June 21, 2019
LYON, France and CAMBRIDGE, Mass. , July 16, 2019 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext: ERYP - Nasdaq: ERYP) announced that its 2019 Annual General Meeting was held in Paris on Friday, June 21, 2019 . At the meeting, all resolutions for which management recommended a vote in favor, were
View HTML
Toggle Summary Monthly information related to total number of voting rights and shares composing the share capital – June 30, 2019
LYON, France , July 02, 2019 (GLOBE NEWSWIRE) -- Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon – France Listing markets: Euronext Paris from Euronext (Market segment C -  ISIN Code: FR0011471135- Symbol: ERYP) & Nasdaq Global Select Market in the United-States
View HTML
Toggle Summary ERYTECH Announces Enrollment of First Patient in Phase 2 Clinical Trial Evaluating Eryaspase in TNBC
LYON, France and CAMBRIDGE, Mass. , June 26, 2019 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug substances inside red blood cells, today announced that the first patient has been
View HTML
Toggle Summary ERYTECH Announces Immune Modulation Strategic Collaboration with SQZ Biotechnologies
LYON, France and CAMBRIDGE, Mass. , June 24, 2019 (GLOBE NEWSWIRE) -- ERYTECH Pharma (ERYTECH) (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug substances inside red blood cells (RBCs), announced today that it
View HTML
Toggle Summary ERYTECH Announces Opening of Operations at its New Princeton, NJ GMP Manufacturing Facility
Inauguration event held last week to officially open 30,000 sq. ft GMP manufacturing facility constructed in Princeton, NJ to produce lead product candidate eryaspase in the United States PRINCETON, N.J. and CAMBRIDGE, Mass. and LYON, France , June 24, 2019 (GLOBE NEWSWIRE) -- ERYTECH Pharma
View HTML
Toggle Summary ERYTECH Announces the Availability of the Documents for its Annual General Meeting to be held on June 21, 2019
LYON, France , May 31, 2019 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris: ERYP – Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug substances inside red blood cells, today announced that the availability of the documents for its
View HTML
Toggle Summary ERYTECH Announces FDA’s Authorization to Proceed with Phase 3 Trial for Eryaspase in Pancreatic Cancer in the United States
Investigational New Drug Application reviewed and accepted Enrollment of US patients expected to begin in Q3 2019 Clinical trial authorizations now obtained in all twelve participating countries LYON, France and CAMBRIDGE, Mass. , May 13, 2019 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext: ERYP -
View HTML
Toggle Summary ERYTECH Provides Business Update and Reports Financial Results for First Quarter 2019
Conference call and webcast on Tuesday, May 7 at 2:30 pm CET/8:30 am EDT TRYbeCA1, pivotal Phase 3 trial for eryaspase in second line pancreatic cancer, actively enrolling patients Construction of new manufacturing site in Princeton and extension of Lyon facility completed Cash position of €110.5
View HTML
Toggle Summary ERYTECH proposes the appointment of Dr. Jean-Paul Kress as Chairman of the Board of Directors
LYON, France , May 06, 2019 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells , is announcing that the Board of Directors will
View HTML
Toggle Summary ERYTECH to Host on May 7, 2019 First Quarter Conference Call and Business Update
LYON, France , May 02, 2019 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will host its 2019 first
View HTML
Top